20314 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
PYRROLE AMIDE COMPOUND AND USE THEREOF
#302LYMPH DIRECTING PRODRUGS
#303Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
#304HBV inhibitor and its use
#305SUSTAINED RELEASE FORMULATION FOR LOCAL DELIVERY OF CDK9 INHIBITORS
#306Pharmaceutical combination for the treatment of cancer
#307METHODS OF TREATING OR PREVENTING PRETERM LABOR
#308APREMILAST LIPOPHILIC TOPICAL PHARMACEUTICAL COMPOSITIONS
#309Therapeutic treatment of microsatellite unstable cancers
#310Prodrugs of urolithins and uses thereof
#311INTRANASAL DESMOPRESSIN ADMINISTRATION
#312TREATING THE CAUSATIVE AGENT IN ADHESIOGENESIS
#313USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE
#314NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
#315METHOD
#316ANTIBACTERIAL COMPOUNDS
#317METHODS FOR TREATING OR PREVENTING CANCER IN A KRAS-VARIANT PATIENT AND FOR DIAGNOSING RISK OF DEVELOPING MULTIPLE PRIMARY BREAST TUMORS
#318ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS
#319HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF
#320Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
#321Pyrrole compounds
#322INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES
#323Substituted benzothiophene analogs as selective estrogen receptor degraders
#324Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
#325CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS
#326TRICYCLIC SPIRO COMPOUND
#327Combination therapies using immuno-dash inhibitors and PGE2 antagonists
#328ANIMAL FEED COMPOSITION AND USE THEREOF
#329Compounds for the treatment of cancers associated with human papillomavirus
#330Composition comprising high purity pyrrole derivative and method for preparation thereof
#331Pharmaceutical combinations for the treatment of cancer
#332CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS
#333Anti-cancer agents and preparation thereof
#334INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE
#335Pharmaceutical combination for the treatment of melanoma
#336Method for the treatment of pancreatitis
#337SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS
#338Sulcardine administration for treatment of acute atrial fibrillation
#339ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#340Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
#341INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE
#342METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN
#343COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
#344PAPD5 INHIBITORS AND METHODS OF USE THEREOF
#345PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING
#346METHODS FOR TREATING GAUCHER DISEASE
#347MICRONEEDLE ARRAY PATCH FOR DRUG DELIVERY AND PRODUCTION METHOD THEREOF
#348SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#349Composition of a drug carrier, pharmaceutical composition thereof, preparation method and use method thereof
#350Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
#351Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
#352SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR TREATMENT OF PANCREATIC CANCER
#353COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION
#354Pharmaceutical combinations for the treatment of cancer
#355NEOANTIGENS AND USES THEREOF
#356Compositions containing exosome carrying NF-κB inhibitors and methods of using thereof
#357MACROGOL 15 HYDROXYSTEARATE FORMULATIONS
#358Compounds for inhibition of inflammation
#359COMBINATION THERAPY FOR PULMONARY HYPERTENSION
#360MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE
#361Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#362Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response
#363METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS
#364Antibodies, pharmaceutical compositions and methods
#365COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
#366COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE
#367PYRROLE DERIVATIVES AS ACC INHIBITORS
#368CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER
#369Pyrrolidine glycosidase inhibitors
#370Thiophene derivatives
#371COMPOUND AND USE THEREOF
#372SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
#373Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
#374METHODS AND COMPOSITIONS FOR TREATING MELANOMA
#375Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
#376PAPD5 inhibitors and methods of use thereof
#377Androgen Receptor Modulator And Uses Thereof
#378Use of NOX inhibitors for treatment of cancer
#379SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS
#380Novel class of compounds for the treatment of cardiovascular disease.
#381COMBINATION THERAPY
#382SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES
#383Pyrrolidine and piperidine compounds
#384READY-TO-USE, TERMINALLY STERILE PACKAGING FOR SURGICAL ANTISEPTIC AND METHOD OF USE
#385Inhibitors of metallo-beta-lactamases
#386NOVEL KINASE FOR TREATING AND PREVENTING FUNGAL INFECTIONS, AND USE THEREOF
#387LHRH-CONJUGATED PRODIGIOSIN AND USES THEREOF
#388CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
#389Ferrochelatase inhibitors and methods of use
#390TREATMENT AND PREVENTION OF VIRAL INFECTION
#391Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer
#392TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
#393Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
#394Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#395Therapeutics for the treatment of glaucoma
#396Sulcardine salts
#397P2RX7 modulators in therapy
#398COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES
#399Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
#400TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS
#401TRPA1 ANTAGONISTS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS
#402Anti-C10orf54 antibodies and uses thereof
#403Compounds
#404Pharmaceutical combinations for the treatment of cancer
#405RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
#406Inhibitors of metallo-beta-lactamases
#407Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
#408Sustained-release triptan compositions and method of use the same through subdermal route or the like
#409Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
#410MODULATORS OF THE INTEGRATED STRESS PATHWAY
#411Thioindirubins
#412METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
#413Pyrrole compounds
#414Cyclic peroxides as prodrugs for selective delivery of agents
#415Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
#416Methods and compositions for treatment of endothelin B receptor expressing tumors
#417NANOPARTICLE COMPOSITIONS OF ENDOTHELIN B RECEPTOR ANTAGONISTS
#418Stable amorphous Eliglustat premix and process for the preparation thereof
#419Sulcardine salts
#420MYC G-quadruplex stabilizing small molecules and their use
#421STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF
#422Enteric combination therapy
#423Targeting Macrophages to Modulate Electrical Conduction in the Heart
#424COMBINATION OF A BTK INHIBITOR AND AN INHIBITOR OR CDK9 TO TREAT CANCER
#425METHODS OF INHIBITING ENDOTHELIN B RECEPTOR EXPRESSING TUMOR METASTASES
#426Compounds for the treatment of cancers associated with human papillomavirus
#427Benzofuran derivatives and their use as bromodomain inhibitors
#428COMBINATION THERAPY FOR IMMUNOLOGICAL DISEASES
#429PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS
#430Inhibitors of hepatitis C virus replication
#431Oral solid dosage form composition having improved disintegration and preparation method therefor
#432TRPV4 antagonists
#433Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
#434STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES
#4353-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
#436Polymer derivatives having particular atom arrangements
#437PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER
#438METHODS AND COMPOSITIONS FOR TREATING FIBROTIC INTERSTITIAL LUNG DISEASE
#439METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION
#440Prodrugs of urolithins and uses thereof
#441PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT
#442Benzothiophene estrogen receptor modulators
#443Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
#444Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
#445Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
#446Method for Predicting Effectiveness of Angiogenesis Inhibitor
#447Targeting kinases for the treatment of cancer metastasis
#448PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT
#449TREATMENT WITH NMDA RECEPTOR MODULATORS
#450PPAR agonists
#451COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
#452Sulcardine administration for treatment of acute atrial fibrillation
#453Antifungal agents
#454PHARMACEUTICALS COMPOSITIONS FOR TREATMENT OF ATOPIC DERMATITIS
#455Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
#456Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy
#457METHODS FOR TREATING CANCER
#458Pharmaceutical combination for the treatment of cancer
#459Methods of treating or preventing preterm labor
#460COMPOSITION FOR PREVENTING OR TREATING EGFR-MUTANT NON-SMALL CELL LUNG CANCER
#461EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF
#462Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
#463Compositions and methods for treating neurodegenerative diseases
#464Tricyclic spiro compound
#465HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
#466Methods and compositions for the inhibition of PIN1
#467Methods, agents, and compositions for the treatment of acute myeloid leukemia
#468INHIBITORS OF BRUTONS TYROSINE KINASE
#469INTRANASAL DESMOPRESSIN ADMINISTRATION
#470Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
#471OLIGOMER-OPIOID AGONIST CONJUGATES
#472CHEMICAL ENTITIES THAT KILL SENESCENT CELLS FOR USE IN TREATING AGE-RELATED DISEASE
#473COMBINATION THERAPY FOR PULMONARY HYPERTENSION
#474Citric acid derivative
#475Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
#476Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis
#477Combination therapies using immuno-dash inhibitors and PGE2 antagonists
#478Type III deiodinase inhibitors and uses thereof
#479Prognostic methods and systems of treatment for acute lymphoblastic leukemia
#480Oral eliglustat transmucosal delivery system
#481Compositions and methods of treating cardiac hypertrophy and heart failure
#482Pharmaceutical compositions and the treatment of overactive bladder
#483SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS
#484Aptamer-drug conjugate and use thereof
#485MODIFIED DOXORUBICIN COMPOSITIONS AND METHODS
#486Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
#487Neuroprotective compounds and methods of use
#488Telomerase activating compounds for use in fertility and related applications
#489Cell-protective compounds and their use
#490Aryl hydrocarbon receptor modulators
#491Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
#492SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS
#493TREATMENT OF MENTAL, MOVEMENT AND BEHAVIORAL DISORDERS
#494COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#495Antifungal agents
#496IRE-1α inhibitors
#497METHODS FOR TREATING OR PREVENTING CANCER IN A KRAS-VARIANT PATIENT AND FOR DIAGNOSING RISK OF DEVELOPING MULTIPLE PRIMARY BREAST TUMORS
#498Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
#499TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY
#500Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
#501Cyclic peroxides as prodrugs for selective delivery of agents
#502Anticancer compounds
#503EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS
#504PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
#505Compounds for use in treatment of mucositis
#506PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
#507N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor
#508Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
#509OLIGOMER-OPIOID AGONIST CONJUGATES
#510USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
#511INHIBITORS OF T CELL RECEPTOR AND USES THEREOF
#512DELAYED-RELEASE FORMULATIONS, METHODS OF MAKING AND USE THEREOF
#513Anti-cancer agents and preparation thereof
#514Furane derivatives as inhibitors of ATAD2
#515CDK1 inhibitors of acetyl chrysin mannich base derivatives, synthesis and use thereof
#516TRPV4 antagonists
#517Dash inhibitors, and uses related thereto
#518TREATMENT AND PREVENTION OF VIRAL INFECTION
#519Tissue factor-targeted antibody-drug conjugate
#520Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
#521Methods for treating Gaucher disease
#522Anti-C10ORF54 antibodies and uses thereof
#5232-pyrrolidine phenylhydrazides antibacterial agents
#524COMPOSITIONS AND METHODS FOR TREATING HCV
#525Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
#526Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck
#527Method of Preparing Solid Dispersions of Active Pharmaceutical Ingredients
#528DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
#529K-RAS MUTATIONS AND ANTAGONISTS
#530Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#531PHARMACEUTICAL COMBINATIONS
#532FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof
#533INHIBITORS OF HEPATITIS C VIRUS REPLICATION
#534Substituted Chromanes and Method of Use
#535Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof
#536Benzothiophene estrogen receptor modulators
#537Prodigiosin analogs
#538Methods for the treatment of cardiac hypertrophy
#539Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists
#540COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
#541TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
#542LYMPH DIRECTING PRODRUGS
#543INHIBITORS OF BRUTON'S TYROSINE KINASE
#544MYC G-quadruplex stabilizing small molecules and their use
#545Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions
#546FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
#547FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
#548Voltage-dependent t-type calcium channel blocker
#549COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ATRIAL FIBRILLATION
#550Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
#551NOVEL PHARMACEUTICAL USES
#5522,3-epoxy succinyl derivative, preparation method and use thereof
#553D-proline derivatives as SAP depleting agent
#554Oligomer-opioid agonist conjugates
#555Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
#556Medicament used for treating hypertension
#557Medicament for use in treating cardiovascular and cerebrovascular diseases
#558Medicament for use in treating fatty liver, hepatitis and cirrhosis
#559NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
#560Coumarin based HSP90 inhibitors with urea and ether substituents
#561Polymer derivatives having particular atom arrangements
#562METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE
#563Extended, delayed and immediate release formulation method of manufacturing and use thereof
#564CNS-accessible pharmacological chaperones for treatment of acid β-glucosidase-related disease states
#565Prodrugs of urolithins and uses thereof
#566Derivatives of Xanthone Compounds
#567Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
#568DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM
#569METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS
#570Purine compounds possessing anticancer activity
#571Compounds for the treatment of cancers associated with human papillomavirus
#572METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF
#573Multikinase inhibitors for use in the treatment of cancer
#574Small molecule agonists and antagonists of NR2F6 activity
#575COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#576Antibodies, pharmaceutical compositions and methods
#577Citric acid derivative
#578Tricyclic spiro compound
#579ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES
#580Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
#581Methods of treating muscular dystrophy
#582Substituted pyrrolidines as mGluR5 antagonists
#583Composition comprising diacid derivatives and their use in the treatment of collagenic eye disorders
#584PHARMACEUTICAL FORMULATION FOR BEDWETTING AND METHOD OF USE THEREOF
#585Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#5866-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
#587Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
#588TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
#589Pyrrole compound, compositions and process for preparation thereof
#590COMPOSITION AND METHODS FOR TREATING SLEEP DISORDERS
#591Modulators of CA release-activated CA (CRAC) channels and pharmaceutical uses thereof
#592Methods of treating muscular dystrophy
#5936-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
#594Benzothiophene estrogen receptor modulators
#595Synergistic auristatin combinations
#596IRE-1α inhibitors
#5973-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
#598Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
#599Type III deiodinase inhibitors and uses thereof
#600Compositions and methods for treating neurodegenerative diseases